title: Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome.
abstract: OBJECTIVE
  To evaluate changes in adiposity in congenital GH/IGF-1 deficient children during hGH or IGF-1 treatment.
  
  
  METHODS
  27 children with congenital isolated growth hormone deficiency (cIGHD) treated with hGH for 2.5-15.2 years (mean 10.0 ± 3.4), 18 children with congenital multiple pituitary hormone deficiency (cMPHD), treated with hGH for 2.3-17.9 years (mean 6.1 ± 4.3), and 14 children with Laron syndrome (LS) treated with IGF-1 for 1.2-12 years (mean 5.5 ± 3.7) were studied. Changes in the degree of adiposity were evaluated by subscapular skinfold thickness (SSFT), before, during and up to 2 years after treatment. All the children had various degrees of obesity.
  
  
  RESULTS
  During the pretreatment period, cIGHD patients showed little changes in SSFT (P = 0.45), cMPHD and LS patients showed an increase in SSFT (P = 0.01, P = 0.06 respectively). During the initial 0.6-1.1 years of hGH/IGF-1 treatment, the SSFT decreased in all 3 groups (P < 0.001), while during subsequent years a significant increase in SSFT (P < 0.001) was observed, in all types of patients, notably in females. Only the cIGHD patients demonstrated a significant correlation between the degree of SSFT decrease and height SDS gain (R = -0.56, P = 0.002) in the first period of treatment.
  
  
  CONCLUSIONS
  Short term replacement therapy of 0.6-1.1 years with either hGH or IGF-1, induced a reduction in subscapular subcutaneous fat whereas prolongation of therapy led to an increase in the subcutaneous fat.
authors.affiliation: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Orly
authors.initials: O
authors.lastname: Bisker-Kassif
authors.affiliation: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Rivka
authors.initials: R
authors.lastname: Kauli
authors.affiliation: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Pearl
authors.initials: P
authors.lastname: Lilos
authors.affiliation: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:Laronz@clalit.org.il.
authors.forename: Zvi
authors.initials: Z
authors.lastname: Laron
mesh_terms: D050154:Adiposity; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004393:Dwarfism, Pituitary / Q000151:congenital / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D019382:Human Growth Hormone / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D007018:Hypopituitarism / Q000151:congenital / Q000188:drug therapy* / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D046150:Laron Syndrome / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D010907:Pituitary Hormones / Q000172:deficiency; D012540:Scapula; D012737:Sex Factors; D012885:Skinfold Thickness; D050151:Subcutaneous Fat / Q000378:metabolism*
chemical_list: D010907:Pituitary Hormones; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I